RYTM vs. ARVN, MORF, AKRO, PLRX, ANNX, ROIV, ELAN, ASND, LEGN, and CERE
Should you be buying Rhythm Pharmaceuticals stock or one of its competitors? The main competitors of Rhythm Pharmaceuticals include Arvinas (ARVN), Morphic (MORF), Akero Therapeutics (AKRO), Pliant Therapeutics (PLRX), Annexon (ANNX), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), and Cerevel Therapeutics (CERE). These companies are all part of the "pharmaceutical preparations" industry.
Rhythm Pharmaceuticals (NASDAQ:RYTM) and Arvinas (NASDAQ:ARVN) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk, community ranking and dividends.
Rhythm Pharmaceuticals has higher revenue and earnings than Arvinas. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.
In the previous week, Arvinas had 1 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 8 mentions for Arvinas and 7 mentions for Rhythm Pharmaceuticals. Arvinas' average media sentiment score of 1.01 beat Rhythm Pharmaceuticals' score of 0.69 indicating that Arvinas is being referred to more favorably in the news media.
Rhythm Pharmaceuticals has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500.
Arvinas has a net margin of -185.09% compared to Rhythm Pharmaceuticals' net margin of -297.91%. Arvinas' return on equity of -64.79% beat Rhythm Pharmaceuticals' return on equity.
Rhythm Pharmaceuticals received 104 more outperform votes than Arvinas when rated by MarketBeat users. Likewise, 65.71% of users gave Rhythm Pharmaceuticals an outperform vote while only 65.40% of users gave Arvinas an outperform vote.
95.2% of Arvinas shares are held by institutional investors. 5.6% of Rhythm Pharmaceuticals shares are held by insiders. Comparatively, 5.2% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Rhythm Pharmaceuticals currently has a consensus target price of $54.33, suggesting a potential upside of 53.44%. Arvinas has a consensus target price of $61.13, suggesting a potential upside of 80.33%. Given Arvinas' stronger consensus rating and higher possible upside, analysts plainly believe Arvinas is more favorable than Rhythm Pharmaceuticals.
Summary
Arvinas beats Rhythm Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Rhythm Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RYTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rhythm Pharmaceuticals Competitors List
Related Companies and Tools
